Download the app
App StorePlay Store
Beige
Login
← All tags

sun pharma

Sun Pharma wins trademark battle as Bombay High Court blocks rival United Biotech

Sun Pharma wins trademark battle as Bombay High Court blocks rival United Biotech

The Bombay High Court ruled in favour of Sun Pharmaceutical Industries in a trademark dispute against United Biotech. It restrained United Biotech from using a similar mark, holding that Sun Pharma’s “Octride” has the stronger claim. The case relates to drugs used for acromegaly and carcinoid tumours, with the judgment protecting Sun’s reputation and goodwill.

Summarised by Beize from a story on The Economic Times on 6 May 2026
Sun Pharma leads as five stocks hit 52 week highs rally up to 25% in a month

Sun Pharma leads as five stocks hit 52 week highs rally up to 25% in a month

The Sensex jumped 940 points as six BSE 100 stocks touched 52 week highs, signaling strong bullish momentum. Adani Ports, Nestle India and Sun Pharma led the outperformance, with several shares gaining sharply over the month. The rally was driven by solid monthly performance and improving investor sentiment as the broader market climbed higher.

Summarised by Beize from a story on The Economic Times on 6 May 2026

Your news, in seconds

App StorePlay Store
Sun Pharma eyes funding swaps and offshore loans for 12 billion Organon deal approval

Sun Pharma eyes funding swaps and offshore loans for 12 billion Organon deal approval

Sun Pharmaceutical Industries is exploring multiple financing routes for its proposed $12 billion acquisition of Organon & Co. Reports say lenders are considering swapping Organon bondholders into Sun Pharma debt, including a possible euro-denominated bond, while Sun Pharma also plans to raise $3 billion to $4 billion in offshore loans. Deal approvals are expected by December.

Summarised by Beize from a story on The Economic Times on 6 May 2026
Sun Pharma jumps into global top 25 as it buys Organon for 11.75 billion

Sun Pharma jumps into global top 25 as it buys Organon for 11.75 billion

Sun Pharma’s acquisition of Organon in a record $11.75 billion deal propels the company into the world’s top 25 pharma players. While chairman Dilip Shanghvi is excited by the leap in scale and ambition, the moment also carries anxiety—highlighting how even “winning” mergers demand careful execution.

Summarised by Beize from a story on The Economic Times on 6 May 2026
Sun Pharma buys Organon for 11 75 billion boosting scale but integration debt could bite

Sun Pharma buys Organon for 11 75 billion boosting scale but integration debt could bite

Sun Pharma’s $11.75 billion acquisition of Organon & Co is set to expand its global footprint, commercial reach, and product diversification, including women’s health and biosimilars. The move aims to strengthen long-term growth, but success will hinge on how smoothly management integrates Organon’s operations and controls the deal’s debt burden.

Summarised by Beize from a story on The Economic Times on 27 Apr 2026
Sun Pharma buys Organon to boost oncology dermatology and women health fast

Sun Pharma buys Organon to boost oncology dermatology and women health fast

Sun Pharma is strengthening its global footprint with the acquisition of New Jersey based Organon. The deal expands its portfolio across dermatology, oncology, and women’s health while creating a route into markets such as China and Brazil. With strong finances underpinning the move, Sun expects quicker returns as it scales the combined capabilities and reach.

Summarised by Beize from a story on The Economic Times on 27 Apr 2026

Never miss a story

App StorePlay Store
Sun Pharma targets its biggest overseas deal as Dilip Shanghvi doubles down on buyouts

Sun Pharma targets its biggest overseas deal as Dilip Shanghvi doubles down on buyouts

Sun Pharma, under Dilip Shanghvi, is preparing its biggest overseas acquisition: a $12.5 billion deal for Organon & Co. The move builds on Shanghvi’s buyout playbook—snapping up firms with strategic value and turnaround potential to drive global expansion. His prior deals, including Ranbaxy and Taro, show how targeted acquisitions can reshape growth across markets.

Summarised by Beize from a story on The Economic Times on 27 Apr 2026
Sun Pharma to buy Organon for 11.75 billion all cash deal

Sun Pharma to buy Organon for 11.75 billion all cash deal

Sun Pharmaceutical Industries has agreed to acquire U.S. drugmaker Organon & Co in an all-cash transaction worth about $11.75 billion including debt. Sun will buy every outstanding Organon share for $14.00 each, giving it full ownership of a company known for women’s health, biosimilars, and established therapies.

Summarised by Beize from a story on The Economic Times on 27 Apr 2026
RIL Paytm and Sun Pharma spark market news as correction bites investors

RIL Paytm and Sun Pharma spark market news as correction bites investors

Indian markets extended a corrective phase as major names brought fresh triggers. RIL, IDFC First Bank and Paytm reported results and company updates, while Sun Pharma is preparing a major overseas acquisition. In the power and metals space, NTPC’s nuclear plan, Adani Green’s battery storage push, Coal India’s import cuts, and updates from Hindustan Zinc and HPCL added momentum.

Summarised by Beize from a story on The Economic Times on 27 Apr 2026
Sun Pharma to acquire Organon for 12 5 billion its biggest deal yet

Sun Pharma to acquire Organon for 12 5 billion its biggest deal yet

Sun Pharma is set to buy US drugmaker Organon for $12.5 billion, expected to be decided at a board meeting over the weekend. The Mumbai-based company will beat the EQT-Gruenthal consortium, paying $4.5 billion for Organon’s equity while taking on $8.5 billion of debt, with an announcement likely tonight or by Monday.

Summarised by Beize from a story on The Economic Times on 26 Apr 2026

Reading on mobile?

App StorePlay Store
Sun Pharma FDA nod for Leqselvi as alopecia drug fight heats up against Pfizer and Eli Lilly

Sun Pharma FDA nod for Leqselvi as alopecia drug fight heats up against Pfizer and Eli Lilly

Sun Pharma’s big US bet is paying off. After spending over INR 4,688 crore to buy Concert Pharma, the company secured rights to Leqselvi for hair growth in alopecia areata patients. The drug has now received US FDA approval, but insiders say the real contest with global giants like Pfizer and Eli Lilly is only beginning.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Bombay High Court bars Meghmani Lifesciences from using Esiraft over confusion with Sun Pharma

Bombay High Court bars Meghmani Lifesciences from using Esiraft over confusion with Sun Pharma

Sun Pharmaceutical has won a trademark dispute in Bombay High Court, which barred Meghmani Lifesciences from using the drug mark “Esiraft.” The court accepted Sun’s claim that Meghmani’s “Esiraft” is visually and phonetically similar to Sun’s “Raciraft,” creating a strong likelihood of consumer confusion and amounting to infringement and passing off.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Sun Pharma bids $13 billion for Organon to leap into global branded drugs

Sun Pharma bids $13 billion for Organon to leap into global branded drugs

Sun Pharmaceutical has made a bold $13 billion bid for US firm Organon & Co., signaling its biggest push to shift from generics toward branded and innovative medicines. Sun is competing with other bidders for Organon, and a successful deal would effectively merge Organon into Sun Pharma, reshaping its global ambitions.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Sun Pharma wins Bombay High Court trademark fight banning Absun and Absun Pharma in decade dispute

Sun Pharma wins Bombay High Court trademark fight banning Absun and Absun Pharma in decade dispute

The Bombay High Court has barred a Navi Mumbai drugmaker from using the brand names “Absun” and “Absun Pharma,” siding with Sun Pharmaceutical Industries. In a long-running trademark dispute, the court ruled the competing names are deceptively similar to Sun Pharma’s established marks, potentially confusing consumers. The verdict effectively ends the decade-long legal battle.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026

Follow your favourite sources

App StorePlay Store
Page 1

The full experience is on mobile.

Swipe through stories, personalise your feed, and save articles for later — all on the app.

Download on the App StoreGet it on Google Play